New indication for Ozempic

Blockbuster drug receives TGA approval for CKD indication, as wholesaler supply restrictions are lifted The TGA has approved glucagon-like peptide-1 receptor agonist (GLP1-RA) drug Ozempic (semaglutide 1.0mg) for a label expansion. It is now indicated as an adjunct to standard of care therapy to reduce the risk of sustained decline of kidney function, and to